During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims.

在COVID-19大流行期间，在柳叶刀呼吸医学杂志上发表的一封信函指出，将血管紧张素转换酶抑制剂，血管紧张素受体阻滞剂和布洛芬与SARS CoV-2感染和并发症的更高风险相关联，当被官方采用时卫生当局，对非甾体类抗炎药的COVID-19的实际管理在全世界所有COVID-19管理规程中均已避免。该手稿从药理学的角度讨论了所提及信件中的弱点，并且还列出了一些重要的矛盾评论文章以及驳斥其主张的临床结果。作者选择反对上述对应关系中提出的每项主张，以确认ACEI，